Cargando…

Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS-CoV-2 disease

BACKGROUND: The new coronavirus 19 disease (COVID-19) represents the current worldwide emergency. According to past evidence, a simple biomarker, such as low free triiodothyronine (fT3) levels, within the framework of euthyroid sick syndrome (ESS), might help to identify patients with unfavourable o...

Descripción completa

Detalles Bibliográficos
Autores principales: Sparano, C., Zago, E., Morettini, A., Nozzoli, C., Yannas, D., Adornato, V., Caldini, E., Vaudo, M., Maggi, M., Petrone, L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632565/
https://www.ncbi.nlm.nih.gov/pubmed/34850365
http://dx.doi.org/10.1007/s40618-021-01714-1
_version_ 1784607776668909568
author Sparano, C.
Zago, E.
Morettini, A.
Nozzoli, C.
Yannas, D.
Adornato, V.
Caldini, E.
Vaudo, M.
Maggi, M.
Petrone, L.
author_facet Sparano, C.
Zago, E.
Morettini, A.
Nozzoli, C.
Yannas, D.
Adornato, V.
Caldini, E.
Vaudo, M.
Maggi, M.
Petrone, L.
author_sort Sparano, C.
collection PubMed
description BACKGROUND: The new coronavirus 19 disease (COVID-19) represents the current worldwide emergency. According to past evidence, a simple biomarker, such as low free triiodothyronine (fT3) levels, within the framework of euthyroid sick syndrome (ESS), might help to identify patients with unfavourable outcomes. OBJECTIVE: Evaluation of ESS significance in hospitalized mild COVID-19 patients. DESIGN: Prospective study, from 1 April 2020 to 31 May 2021. PARTICIPANTS: COVID-19 patients with mild disease at hospital admission. MAIN MEASURES: At hospital admission, eligible patients underwent a complete thyroid function evaluation. Subjects with previous thyroid disease or with thyroid-interfering medications were excluded. Levels of fT3 were correlated to biochemical markers and to patient outcome, the latter considered as favourable in the event of infection recovery and unfavourable in the event of death or transfer to an intensive care unit (ICU). KEY RESULTS: Of 600 screened patients, 506 were eligible for this study. Of those, 94 (19%) died during hospitalization and 80 (18%) required a transfer to ICU. The most frequent thyroid disorder was ESS (57%). Admission levels of fT3 were significantly lower within the unfavourable outcome subgroup (p < 0.001) and were negatively associated with several poor prognostic markers, including IL-6 (p < 0.001). In Kaplan–Meier and Cox regression analyses, fT3 was independently associated with poor outcome and death (p = 0.005 and p = 0.037, respectively). A critical fT3 threshold for levels < 2.7 pmol/l (sensitivity 69%, specificity 61%) was associated with a 3.5-fold increased risk of negative outcome (95%CI 2.34–5.34). CONCLUSION: Low fT3 levels, in the framework of ESS, resulted as being a valid predictor of unfavourable outcomes in a very early stage population of COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40618-021-01714-1.
format Online
Article
Text
id pubmed-8632565
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-86325652021-12-01 Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS-CoV-2 disease Sparano, C. Zago, E. Morettini, A. Nozzoli, C. Yannas, D. Adornato, V. Caldini, E. Vaudo, M. Maggi, M. Petrone, L. J Endocrinol Invest Original Article BACKGROUND: The new coronavirus 19 disease (COVID-19) represents the current worldwide emergency. According to past evidence, a simple biomarker, such as low free triiodothyronine (fT3) levels, within the framework of euthyroid sick syndrome (ESS), might help to identify patients with unfavourable outcomes. OBJECTIVE: Evaluation of ESS significance in hospitalized mild COVID-19 patients. DESIGN: Prospective study, from 1 April 2020 to 31 May 2021. PARTICIPANTS: COVID-19 patients with mild disease at hospital admission. MAIN MEASURES: At hospital admission, eligible patients underwent a complete thyroid function evaluation. Subjects with previous thyroid disease or with thyroid-interfering medications were excluded. Levels of fT3 were correlated to biochemical markers and to patient outcome, the latter considered as favourable in the event of infection recovery and unfavourable in the event of death or transfer to an intensive care unit (ICU). KEY RESULTS: Of 600 screened patients, 506 were eligible for this study. Of those, 94 (19%) died during hospitalization and 80 (18%) required a transfer to ICU. The most frequent thyroid disorder was ESS (57%). Admission levels of fT3 were significantly lower within the unfavourable outcome subgroup (p < 0.001) and were negatively associated with several poor prognostic markers, including IL-6 (p < 0.001). In Kaplan–Meier and Cox regression analyses, fT3 was independently associated with poor outcome and death (p = 0.005 and p = 0.037, respectively). A critical fT3 threshold for levels < 2.7 pmol/l (sensitivity 69%, specificity 61%) was associated with a 3.5-fold increased risk of negative outcome (95%CI 2.34–5.34). CONCLUSION: Low fT3 levels, in the framework of ESS, resulted as being a valid predictor of unfavourable outcomes in a very early stage population of COVID-19. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s40618-021-01714-1. Springer International Publishing 2021-12-01 2022 /pmc/articles/PMC8632565/ /pubmed/34850365 http://dx.doi.org/10.1007/s40618-021-01714-1 Text en © Italian Society of Endocrinology (SIE) 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Sparano, C.
Zago, E.
Morettini, A.
Nozzoli, C.
Yannas, D.
Adornato, V.
Caldini, E.
Vaudo, M.
Maggi, M.
Petrone, L.
Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS-CoV-2 disease
title Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS-CoV-2 disease
title_full Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS-CoV-2 disease
title_fullStr Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS-CoV-2 disease
title_full_unstemmed Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS-CoV-2 disease
title_short Euthyroid sick syndrome as an early surrogate marker of poor outcome in mild SARS-CoV-2 disease
title_sort euthyroid sick syndrome as an early surrogate marker of poor outcome in mild sars-cov-2 disease
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8632565/
https://www.ncbi.nlm.nih.gov/pubmed/34850365
http://dx.doi.org/10.1007/s40618-021-01714-1
work_keys_str_mv AT sparanoc euthyroidsicksyndromeasanearlysurrogatemarkerofpooroutcomeinmildsarscov2disease
AT zagoe euthyroidsicksyndromeasanearlysurrogatemarkerofpooroutcomeinmildsarscov2disease
AT morettinia euthyroidsicksyndromeasanearlysurrogatemarkerofpooroutcomeinmildsarscov2disease
AT nozzolic euthyroidsicksyndromeasanearlysurrogatemarkerofpooroutcomeinmildsarscov2disease
AT yannasd euthyroidsicksyndromeasanearlysurrogatemarkerofpooroutcomeinmildsarscov2disease
AT adornatov euthyroidsicksyndromeasanearlysurrogatemarkerofpooroutcomeinmildsarscov2disease
AT caldinie euthyroidsicksyndromeasanearlysurrogatemarkerofpooroutcomeinmildsarscov2disease
AT vaudom euthyroidsicksyndromeasanearlysurrogatemarkerofpooroutcomeinmildsarscov2disease
AT maggim euthyroidsicksyndromeasanearlysurrogatemarkerofpooroutcomeinmildsarscov2disease
AT petronel euthyroidsicksyndromeasanearlysurrogatemarkerofpooroutcomeinmildsarscov2disease